In its 8th Year, the Biocom Global Life Science Partnering Conference is an exclusive partnering forum that provides senior executives, bankers, venture capitalists, and business development professionals from the leading pharmaceutical and biotech companies to network and do business with one another from around the globe.
The partnering conference and the relationships you build promise to be fruitful for your business ventures this year and for many years to come. We are excited by the prospect of continuing an annual bio-pharma partnering conference that brings together leading deal makers and emerging biotechs from around the world, while providing a local San Diego venue to showcase the impressive accomplishments and progress taking place in one of the top biotech hubs in the world.
Join us in San Diego on February 28th and March 1st, where industry leaders will debate current trends, companies will showcase their latest technologies and all attendees will have the opportunity to schedule one-on-one meetings with leading dealmakers.
New to 2018: BIO’s One-on-One Partnering System:
We heard your concerns and feedback from 2017 and have changed our partnering system platform for our 2018 conference. The Global Life Science Partnering Conference now utilizes BIO’s One-on-One Partnering System. Additionally, after exceeding our meeting space in 2017, we are excited to announce that we have added additional meeting locations and tables for one-on-one meetings in 2018. Participating in one-on-one partnering at the Biocom Global Life Science Partnering Conference is a unique and valuable experience that allows you to meet one-on-one in a private setting with attendees of your choice throughout the length of the entire conference. The partnering system will open the week of January 15th, 2018.
Hear What Others Have to Say:
“Every partnering meeting was great and all the panels were beyond fantastic. I even met a new investor!”
Ross Bundy, CEO, Nanomedical Diagnostics
“Presenting at Biocom this year helped put Forge on the radar of several investors seeking to put money to work in the antibiotic space. The conference not only gave me the opportunity to meet the interested investors face-to-face but also gave me a platform to describe our funding strategy and growth trajectory, which gave us additional momentum leading to upsizing our Series A round. In fact, after my presentation multiple investors that were ‘circling the hoop’ were now ready to jump into the game and asked if they could participate in the Series A financing.”
Zachary Zimmerman, Ph.D., CEO , Forge Therapeutics, Inc.